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scans were made (120 kV, 250 mAs). In the first scan, the phantom 
contained only Solid Water rods. This scan was reconstructed without 
O-MAR to obtain a baseline. In the second scan, rod H was replaced 
with a titanium rod to simulate a patient with a unilateral metallic hip 
prosthesis. For the third scan, also rod E was replaced with a titanium 
rod to simulate a patient with bilateral metallic hip prostheses. Both 
the second and third scan were reconstructed with O-MAR. In each of 
the three reconstructions, cylindrical VOIs (d = 20 mm, l = 42 mm, 
approx. 6400 pixels) were created in each rod using ProSoma 3.3 
(MedCom GmbH, Darmstadt, Germany). Subsequently, the mean CT 
number and the standard deviation were determined in each VOI. 
With a t-test, it was assessed whether the mean CT numbers obtained 
from each VOI in the reconstructions of the patient simulations 
differed significantly (p < 0.01) from the baseline values. 
 
  
Results: In the unilateral simulation, the mean CT number in 10 of the 
19 VOIs was significantly different. However, all differences were 
small (range: -2.4 to +2.3 HU) and therefore not considered of clinical 
relevance. In the bilateral simulation, the mean CT number in 13 of 
the 18 VOIs was significantly different. Apart from rods O and T, the 
differences were small (range: -2.0 to +11.8 HU) and therefore not 
clinically relevant. In rods O and T, the difference was respectively -
32.5 and -31.5 HU. Although relatively big, these differences are also 
not clinically relevant as in our external beam radiotherapy planning 
department, beam setups in which a beam enters the PTV through a 
metallic implant are always avoided. 
Conclusions: Our phantom study shows that the CT numbers in O-MAR 
reconstructions of the pelvic area that contain large metal objects are 
accurate enough for clinical use in external beam radiotherapy 
treatment planning. 
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Purpose/Objective: In September 2009 the newly designed digital 
linear accelerator TrueBeam STx (Varian Medical Systems) was 
installed. Over the last three years constancy tests were performed to 
evaluate the stability of this machine. 
Materials and Methods: The linear accelerator is equipped with two 
flattened and two flattening filter free beams of nominal energy 6 MV 
and 10 MV. As of November 2009, the output was checked daily using 
a PTW LinaCheck device; and since March 2010, energy and symmetry 
were checked weekly using a PTW QuickCheck device. IsoCal 
verification, a method to quantify deviation from the kV and MV 
imaging isocenters to the treatment isocenter and to determine 
gantry isocenter instabilities, was performed on a daily basis. For 
comparison, a weekly kV isocenter check using a cube with an internal 
metal ball, and monthly gantry starshots were performed. The 
performance of the high definition multi leaf collimator (HD MLC) was 
tested initially on a weekly basis. More recently the frequency was 
changed to daily. MLC performance was verified using Picket Fence 
tests and by analysing trajectory logfiles.  
Results: During the first two years the output increased by 0.3 % per 
month, after which the output became stable. Variation in symmetry 
was larger for FFF beams compared to flattened beams due to the 
high sensitivity of FFF beam symmetry on the detector array setup. 
The symmetry of the flattened beams drifted by approximately 1% and 
had to be adjusted in June 2012. No drift was observed for the FFF 
beams. The two imaging isocenters have never differed by more than 
0.4 mm from the treatment isocenter. There exists no 
recommendation for the frequency of MLC initialisation. Our analysis 
of the daily Picket Fence test showed that initialisation should be 
done on a weekly basis and Picket Fence test on a daily basis. It 
occurred four times during the three-year period, that one of the MLC 
leafs had a positioning discrepancy of between 1-2 mm. This was 
detected in the morning by the Picket Fence test. The error was not 
detected as an interlock by the linear accelerator (linac) nor recorded 
in the trajectory logfiles. Trajectory logfiles only record the primary 
and not the secondary readout. Therefore QA based only on trajectory 
logfiles is not sufficient. 
Conclusions: It is important to perform extended QA for linacs which 
are new on the market, to evaluate their weaknesses and strengths. In 
our opinion the strength of the TrueBeam is the high precision of the 
imaging system; a weakness being the stability of the monitor 
chamber and the design of the HDMLC. An interlock for the MLC is 
only triggered if the deviation between the primary and secondary 
position is larger than 2.5 mm. We have experienced a slight drift of 
the flattening filter with time, which altered the symmetry of the 
flattened beams. 
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Purpose/Objective: The experience on the image-guided preclinical 
studies, conducted on two dedicated kilovoltage small animal 
irradiators, are to be presented (XRad-320 and XRad-225Cx, Precision 
X-Ray Inc., North Branford, CT). 
Materials and Methods: Two platforms of preclinical stereotactic 
irradiator are used, which are capable of delivering high dose, high 
dose-gradient small field (circular, square, and custom shape) 
irradiation utilizing a x-ray image guidance system. The XRad-320 is 
composed of a fixed radiation source and a computer-controlled 2D 
localization system. In contrast, the XRad-225Cx can deliver multi-
angle beams with 3D localization based on a built-in cone-beam 
computed tomography. The basic science experiments performed on 
two systems are: hemibrain irradiation utilizing a custom D-shape 
collimator to examine the genetic basis for radioresistance in 
glioblastoma; a single fraction of 10 Gy whole brain irradiation using a 
10 mm circular collimator to study the association of drug addiction 
with hippocampal neurogenesis; 90 Gy single fraction irradiation using 
1 - 5 mm collimators to study the response of normal lung; orthotopic 
lung and prostate tumor treatment in rats using high dose stereotactic 
irradiation; 16 Gy single fraction irradiation of age-related macular 
degeneration with the application of anti-phosphatidylserine (anti-PS) 
antibodies in a mouse model; a single fraction dose escalation to study 
the effects of stem cell enhanced fat grafts to mitigate cutaneous 
radiation injury. Various preclinical imaging modalities (MRI, 
ultrasonography, bioluminescence imaging) are used to aid in planning 
and/or response assessment. 
Results: Hemibrain study showed that the loss of conditional p53 and 
PTEN genes, alone or in combination could result in radioresistance in 
an actively dividing population in the brain. The whole brain 
irradiation study in animal model indicated that the suppression of 
neurogenesis in adult hippocampus enhanced vulnerability with a 
variety of drug addictions and its relapse. In normal lung of rats, the 
obliteration of alveoli, hyperplasia of the bronchiolar epithelium, and 
small inflammatory of cells were observed in response to small high 
dose irradiation. Orthotopic tumors are dramatically in size and their 
activity are effectively suppressed compared to control groups. 
Preliminary data indicated that anti-PS antibodies with radiation have 
a potentiating effect in blocking choroidal neovascularization. 
Ulceration occurred on all irradiated skin of various doses within 10 
days post irradiation. Peak ulceration was weakly correlated with 
doses, while average ulceration presented a stronger correlation. 
Conclusions: The radiation effects in various preclinical small animal 
models were successfully studied.  
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Purpose/Objective: To investigate the advantages in dosimetry, 
patient comfort and positioning accuracy when using the newly 
developed Sagittilt® (Orfit Industries, Wijnegem, Belgium) prone 
breast board. 
Materials and Methods: A careful clinical introduction of Sagittilt® has 
been initiated: Phase 1: pre-clinical treatment planning study and 
Phase 2: prospective clinical trial (still ongoing). During the pre-
clinical phase, 14 patients with breast cancer were scanned in supine 
and prone position and treatment plans were created to investigate 
dosimetrical advantages of Sagittilt®. The second phase started with 
the clinical treatments of (to date) 5 patients in prone position. This 
early clinical phase focused on patient comfort assessed by an in-
house developed questionnaire completed by the patients. Positioning 
accuracy has been assessed by daily online cone-beam CT acquisition 
(pre-RT CBCT), followed by a post-RT CBCT in order to investigate 
stability of positioning over time. 
Results: The pre-clinical treatment planning study confirmed non-
significant differences on target coverage (V95%-107% of the PTV) and 
on heart dose, while a significant reduction of the ipsilateral lung and 
slightly higher dose to the contralateral breast were observed. The 
early clinical phase eliminated the increased contralateral breast 
dose, revealed good-excellent patient comfort, while the setup error 
remained low (individual systematic and random errors were: 0-3 mm 
and 0.8-2.5 mm). The residual error (ie. the error observed between 
the two CBCT) could rise up to 7 mm (at the 2nd patient Figure 1.) 
especially if treatment execution exceeds 10 minutes.  
 
Conclusions: Our methodology for the clinical introduction of 
Sagittilt® proved to be safe. Our current data showed promising 
results for dosimetry and positioning accuracy. Special attention 
should be paid to reduce the overall treatment time to keep residual 
error as low as possible. 
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Purpose/Objective: High-quality radiotherapy (RT) treatment 
planning requires the combination of information arising from multiple 
medical imaging modalities. For this reason, RT implies the setup and 
the management of complex flows of images between the various 
modalities and software of the hospital. Even though biomedical 
images are most commonly stored and transferred using the DICOM 
standard, it remains hard to automatize and optimize these clinical 
flows that are very specific to each hospital. This stems from the fact 
that programming the DICOM network protocol requires both a high 
level of familiarity with the DICOM standard as well as substantial 
experience in computer programming. This motivates the introduction 
of the Orthanc software in the medical practice to improve the RT 
imaging workflow. 
Materials and Methods: Orthanc is an open-source, easy-to-use, 
lightweight and scriptable DICOM store. It takes advantage of the 
DCMTK toolkit for powerful DICOM handling abilities. Multiple 
instances of Orthanc can be easily and freely deployed in the hospital 
network. Orthanc comes bundled with an embedded Web interface 
that allows the end-users to browse and interact with the content of 
the DICOM store from any computer. Orthanc can be setup as a bridge 
between multiple DICOM modalities, which improves the 
interoperability between proprietary systems by decoupling them. 
Furthermore, Orthanc features a rich scripting environment: It can be 
driven from any computer language to automate and optimize clinical 
processes. Orthanc is written in C++ for maximum speed, and 
emphasis is put on the quality and the automated validation of its 
source code. 
Results: Orthanc is currently used in our Institution to improve two 
real-world clinical processes. Firstly, Orthanc is deployed as a buffer 
for PET scans between Nuclear Medicine (NM) and RT departments. 
These images are indeed systematically purged from the Treatment 
Planning System (TPS) on a daily basis. Orthanc enables the RT 
physicists to immediately find the purged images and restore them 
back from Orthanc into the TPS on the fly, without any interaction 
with the NM team, hence accelerating the clinical processes. 
Secondly, another instance of Orthanc is configured to gather the in-
room images that are produced during the RT treatments. This opens 
the path to the automated assessment of the quality of the patient 
positioning and to the clinical research about adaptive radiotherapy in 
our hospital. 
Conclusions: The open-source Orthanc software provides medical 
physicists with a powerful environment to make the image flows more 
robust and automated in RT departments.  
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Purpose/Objective: Over recent years, there has been an increasing 
interest in the use of stereotactic body radiotherapy (SBRT) in the 
management of low and intermediate risk prostate adenocarcinoma. A 
number of small studies and single centre series have been published 
demonstrating biochemical progression free survival rates (bPFS) at 3 
to 4 years between 90% - 100%, with long term grade 3 rectal and 
urinary toxicity no higher than 3%. The majority of these series have 
used Cyberknife™ (Accuray Inc., Sunnyvale, CA) with an international 
randomised controlled study underway, comparing SBRT delivered 
using Cyberknife, to surgery and to conventionally fractionated 
intensity modulated radiotherapy. 
Materials and Methods: Six patients previously treated with 
conventional radical radiotherapy were selected to represent a typical 
range of prostate shapes and sizes. Delineation of the prostate alone 
(CTV) and all organs at risk (OARs) was performed by one consultant 
clinical oncologist. A margin of 3mm for CyberKnife and 5mm for 
Rapicarc were used to create PTVs. Plans that deliver at least 35Gy in 
5 fractions to at least 99% of the PTV (PTV35Gy>99%) were then 
created using Accuray Multiplan v.4.5 (Ray-tracing algorithm) and 
Varian Eclipse v.10 (AAA algorithm). SBRT dose constraints that are 
typically employed were used to optimise doses to the rectum and 
bladder without compromising PTV coverage (Rectum V18 <50%, V28 
<20% and V36 <1cc; bladder V18 <40%, V37 <10cc). Plans were 
transferred to a water equivalent phantom and delivered doses were 
measured for both systems using radiochromic film.  
Results: Both planning systems achieved a planned dose PTV 
heterogeneity of <13% in all six patients. The planned OAR constraints 
were achieved for all patients for both systems. We aim to dose 
escalate using both platforms to assess which platform is first to fail 
the constraints. Figure 1 shows an example of comparison CyberKnife 
and Rapidarc plans for the same patient.  
 
  
Conclusions: We have shown that in terms of both planned and 
delivered dosimetry, Rapidarc is comparable to Cyberknife in SBRT for 
prostate cancer. The additional benefit of arc therapy is the 
comparatively short delivery time. In addition there is both a larger 
availability of radiotherapy centres equipped to deliver arc therapy, 
and a larger number of arc capable machines within each centre. An 
international, platform independent, clinical trial is urgently required 
to confirm an equal clinical benefit with other platforms. 
 
